Inozyme Pharma, lead candidate INZ-701, is currently in clinical development for ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis. The company expects to reach an agreement on a pivotal study in ...

BOSTON--(BUSINESS WIRE)--Inozyme Pharma Inc., a biotechnology company developing novel medicines to treat rare and life-threatening mineralization disorders, today announced the addition of three ...

Following meetings with the FDA and the European Medicines Agency's Paediatric Committee, Inozyme Pharma Inc (NASDAQ:INZY) updated its global development strategy for INZ-701, a treatment for ENPP1 ...

Inozyme Pharma, Inc. has announced the postponement of its 2025 Annual Meeting of Stockholders, originally scheduled for June 25, due to its pending acquisition by BioMarin Pharmaceutical Inc. If the ...

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (“Inozyme”) (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of ...

BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (INZY) (Nasdaq: INZY)(“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for ...

BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (INZY) (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for ...

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, ...

BOSTON--(BUSINESS WIRE)--Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today the ...

Inozyme Pharma has hired Sanjay Subramanian as SVP and CFO, as well as Soojin Kim as SVP and chief technical operations officer. Subramanian’s background includes 20 years of experience in corporate ...